 |
| Frank Niemeir/AJC |
| Harold Shlevin, CEO of Tikvah Therapeutics, the Atlanta biotechnology company that plans to market the anti-anxiety drug within a few years, says the potential market is enormous. |
Services »Tell us what you think about the site
Customer Care »
Vacation stops, manage subscriptions and more
AJC Services
Sections
Other Editions
Guides
Visitor Agreement | Privacy Statement
© 2009 The Atlanta Journal-Constitution